CartiHeal Performs First Agili-C™ Cartilage Repair Implantation Procedure in Maryland

KFAR SABA, Israel, Oct. 15, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C™ implant, as part of Investigational Device Exemption (IDE) clinical study by Dr. Jason M. Scopp, orthopedic surgeon and Director of Joint Preservation Center at Peninsula Orthopaedic Clinic in Salisbury, Maryland.

The clinical study will involve a minimum of 250 study patients, currently 241 patients have already been enrolled.

You can read more

CartiHeal Performs First Agili-C™ Cartilage Repair Implantation Procedure in Maryland

Israeli medtech company CartiHeal to be acquired for $500 million by Bioventus

Peregrine Ventures invests in Ribon Therapeutics

Peregrine Ventures invests in Nectin Therapeutics

Kahr Medical is joining Peregrine's portfolio

Wix Acquires Rise.ai

Memic Receives FDA De Novo Marketing Authorization and launches a $96M round

The HearO app, By Cordio Medical has been granted breakthrough device designation by the FDA

Israel's Prime Minister Netanyahu Visits Aleph Farms Plant for the Production of Cultured Meat

OutSense’s AI looks for life-threatening diseases in human waste

Aleph Farms Introduces AlephZero

Recent Posts